<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370408</url>
  </required_header>
  <id_info>
    <org_study_id>NSH 940</org_study_id>
    <nct_id>NCT01370408</nct_id>
  </id_info>
  <brief_title>Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients</brief_title>
  <official_title>A Unique Schedule of Palonosetron, Ondansetron, and Dexamethasone for the Prevention of Delayed Nausea and Vomiting in Patients Receiving Moderately Emetogenic Myeloablative Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northside Hospital, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blood and Marrow Transplant Group of Georgia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northside Hospital, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, patients will receive ondansetron 8mg and dexamethasone 10mg intravenously 30
      minutes prior to myeloablative preparative chemotherapy until the last day of chemotherapy.
      On the final day of chemotherapy, palonosetron 0.25mg and dexamethasone 10mg will be
      administered intravenously 30 minutes prior to the chemotherapy. If the chemotherapy regimen
      is only 1 day of the chemotherapy then only palonosetron and dexamethasone will be
      administered 30 minutes prior to chemotherapy. Dexamethasone 8mg once daily will be given
      orally for 2 days following chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to decrease this delayed CINV, the investigators have developed a unique schedule of
      antiemetics that takes advantage of palonosetron's long elimination half-life (40 hours). In
      this study, patients will receive ondansetron 8mg and dexamethasone 10mg intravenously 30
      minutes prior to myeloablative preparative chemotherapy until the last day of chemotherapy.
      On the final day of chemotherapy, palonosetron 0.25mg and dexamethasone 10mg will be
      administered intravenously 30 minutes prior to the chemotherapy. If the chemotherapy regimen
      is only 1 day of the chemotherapy then only palonosetron and dexamethasone will be
      administered 30 minutes prior to chemotherapy. Dexamethasone 8mg once daily will be given
      orally for 2 days following chemotherapy. The investigators hypothesize that this antiemetic
      schedule will significantly reduce the delayed CINV compared to historical controls
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response Rate for Delayed Chemotherapy Induced Nausea &amp; Vomiting</measure>
    <time_frame>120 hours</time_frame>
    <description>Proportion of patients achieving a delayed CINV complete response (CR) defined as no emetic episode and no use of rescue medications during the 24-120 hour period post chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Remission During Acute Phase Post-chemotherapy</measure>
    <time_frame>24 hours</time_frame>
    <description>Proportion of patients achieving an acute CINV CR during the acute phase post -chemotherapy (0-24 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Remission During Overall Chemotherapy Time Period</measure>
    <time_frame>120 hours</time_frame>
    <description>Proportion of patients achieving a CR during the cumulative overall 0-120 hour time period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Control Rate for Nausea &amp; Vomiting</measure>
    <time_frame>120 hours</time_frame>
    <description>Complete control rate (CC; defined as no emetic episodes, no rescue medication use, and no more than mild nausea)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emetic Episodes</measure>
    <time_frame>120 Hours</time_frame>
    <description>Number of emetic episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Who Experience First Emetic Episode Within 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of patients with first emetic episode experienced within 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients That Required First Administration of Rescue Medication Within 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of patients who required the use of rescue medication (lorazepam, prochlorperazine, promethazine, metoclopramide, scopolamine, or dronabinol) within the first 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients That Experience Treatment Failure Within the First 24 Hours</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of patients with first emetic episode or time to administration of rescue therapy, whichever occurred first, within the first 24 hours</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Palonosetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation
Prior to IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV on the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron</intervention_name>
    <description>Prior to IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO</description>
    <arm_group_label>Palonosetron</arm_group_label>
    <other_name>Aloxi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron</intervention_name>
    <description>Prior to IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV</description>
    <arm_group_label>Palonosetron</arm_group_label>
    <other_name>zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Prior to IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV</description>
    <arm_group_label>Palonosetron</arm_group_label>
    <other_name>Dex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  candidate for high-dose chemotherapy and autologous hematopoietic stem cell
             transplantation

          -  Karnofsky performance status &gt;/= 60%

          -  scheduled to receive one of the following conditioning regimens

          -  BEAM

          -  Oral Busulfan/cyclophosphamide with or without etoposide

          -  Carboplatin/Etoposide

          -  Melphalan

          -  Negative pregnancy test

          -  Must be able to complete a daily nausea/vomiting questionnaire and Quality of Life

        Exclusion Criteria:

          -  Active infection requiring IV antibiotics

          -  Known active hepatitis B and/or hepatitis C or HIV infection

          -  prior non-hematological malignancies at other sites except surgically treated
             non-melanoma skin cancer, superficial cervical cancer or other cancer from which the
             patient had been disease free for &gt;/= 5 years

          -  Uncontrolled medical problems including any of the following

          -  Diabetes mellitus

          -  Cardiac, pulmonary, hepatic or renal disease

          -  myocardial infarction within the past 6 months

          -  Morbid obesity (BMT &gt;40)

          -  History of CNS metastases, psychiatric or CNS disorders interfering with the ability
             to comply with the study

          -  Known hypersensitivity to 5-HT3 antagonists, dexamethasone and/or their components

          -  Intrathecal therapy within 24 hours before starting preparative regimen

          -  Receiving any antiemetic therapy 24 hours before starting preparative regimen

          -  Any 5-HT3 antagonist used as a rescue medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott R Solomon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blood and Marrow Transplant Group of Georgia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <results_first_submitted>October 6, 2016</results_first_submitted>
  <results_first_submitted_qc>December 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 6, 2017</results_first_posted>
  <last_update_submitted>March 16, 2017</last_update_submitted>
  <last_update_submitted_qc>March 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autologous stem cell transplant</keyword>
  <keyword>BEAM</keyword>
  <keyword>Oral busulfan</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Etoposide</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>melphalan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Palonosetron</title>
          <description>All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation
Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
Palonosetron, ondansetron, dexamethasone: Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>treatment failure</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Palonosetron</title>
          <description>All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation
Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
Palonosetron, ondansetron, dexamethasone: Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="20" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Response Rate for Delayed Chemotherapy Induced Nausea &amp; Vomiting</title>
        <description>Proportion of patients achieving a delayed CINV complete response (CR) defined as no emetic episode and no use of rescue medications during the 24-120 hour period post chemotherapy.</description>
        <time_frame>120 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Palonosetron</title>
            <description>All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation
Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
Palonosetron, ondansetron, dexamethasone: Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response Rate for Delayed Chemotherapy Induced Nausea &amp; Vomiting</title>
          <description>Proportion of patients achieving a delayed CINV complete response (CR) defined as no emetic episode and no use of rescue medications during the 24-120 hour period post chemotherapy.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Remission During Acute Phase Post-chemotherapy</title>
        <description>Proportion of patients achieving an acute CINV CR during the acute phase post -chemotherapy (0-24 hours)</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Palonosetron</title>
            <description>All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation
Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
Palonosetron, ondansetron, dexamethasone: Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Remission During Acute Phase Post-chemotherapy</title>
          <description>Proportion of patients achieving an acute CINV CR during the acute phase post -chemotherapy (0-24 hours)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Remission During Overall Chemotherapy Time Period</title>
        <description>Proportion of patients achieving a CR during the cumulative overall 0-120 hour time period</description>
        <time_frame>120 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Palonosetron</title>
            <description>All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation
Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
Palonosetron, ondansetron, dexamethasone: Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Remission During Overall Chemotherapy Time Period</title>
          <description>Proportion of patients achieving a CR during the cumulative overall 0-120 hour time period</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Control Rate for Nausea &amp; Vomiting</title>
        <description>Complete control rate (CC; defined as no emetic episodes, no rescue medication use, and no more than mild nausea)</description>
        <time_frame>120 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Palonosetron</title>
            <description>All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation
Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
Palonosetron, ondansetron, dexamethasone: Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Control Rate for Nausea &amp; Vomiting</title>
          <description>Complete control rate (CC; defined as no emetic episodes, no rescue medication use, and no more than mild nausea)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emetic Episodes</title>
        <description>Number of emetic episodes</description>
        <time_frame>120 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Palonosetron</title>
            <description>All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation
Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
Palonosetron, ondansetron, dexamethasone: Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO</description>
          </group>
        </group_list>
        <measure>
          <title>Emetic Episodes</title>
          <description>Number of emetic episodes</description>
          <units>episodes</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Who Experience First Emetic Episode Within 24 Hours</title>
        <description>Number of patients with first emetic episode experienced within 24 hours</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Palonosetron</title>
            <description>All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation
Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
Palonosetron, ondansetron, dexamethasone: Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Who Experience First Emetic Episode Within 24 Hours</title>
          <description>Number of patients with first emetic episode experienced within 24 hours</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients That Required First Administration of Rescue Medication Within 24 Hours</title>
        <description>Number of patients who required the use of rescue medication (lorazepam, prochlorperazine, promethazine, metoclopramide, scopolamine, or dronabinol) within the first 24 hours</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Palonosetron</title>
            <description>All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation
Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
Palonosetron, ondansetron, dexamethasone: Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Required First Administration of Rescue Medication Within 24 Hours</title>
          <description>Number of patients who required the use of rescue medication (lorazepam, prochlorperazine, promethazine, metoclopramide, scopolamine, or dronabinol) within the first 24 hours</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients That Experience Treatment Failure Within the First 24 Hours</title>
        <description>Number of patients with first emetic episode or time to administration of rescue therapy, whichever occurred first, within the first 24 hours</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Palonosetron</title>
            <description>All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation
Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
Palonosetron, ondansetron, dexamethasone: Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Experience Treatment Failure Within the First 24 Hours</title>
          <description>Number of patients with first emetic episode or time to administration of rescue therapy, whichever occurred first, within the first 24 hours</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Palonosetron</title>
          <description>All patients will receive the following medications prior to and during their high dose chemotherapy for autologous stem cell transplantation
Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
Palonosetron, ondansetron, dexamethasone: Day x-y of IV chemotherapy - ondansetron 8mg IV &amp; Dexamethasone 10 mg IV Day z (last day of chemotherapy) - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>lower extremity edema</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>abdominal cramping</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>rectal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>hiccups</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>mouth pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>mouth sores</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>mucositis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>taste alteration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>throat pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>increased alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>increased ALT</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>increased AST</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>neutropenic fever</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>deconditioning</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>generalized weakness</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>memory changes</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>peripheral neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>dysuria</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>shortness of breath with exertion</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>bruising</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>pruritus</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Scott Solomon</name_or_title>
      <organization>Blood and Marrow Transplant Group of Georgia</organization>
      <phone>404-255-1930</phone>
      <email>ssolomon@bmtga.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

